What do the screening trials really tell us and where do we go from here?

Ruth D. Etzioni, Ian M. Thompson

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Publication of apparently conflicting results from 2 large trials of prostate cancer screening has intensified the debate about prostate-specific antigen (PSA) testing and has led to a recommendation against screening from the US Preventive Services Task Force. This article reviews the trials and discusses the limitations of their empirical results in informing public health policy. In particular, the authors explain why harm-benefit trade-offs based on empirical results may not accurately reflect the trade-offs expected under long-term population screening. This information should be useful to clinicians in understanding the implications of these studies regarding the value of PSA screening.

Original languageEnglish (US)
Pages (from-to)223-228
Number of pages6
JournalUrologic Clinics of North America
Volume41
Issue number2
DOIs
StatePublished - May 2014

Keywords

  • Clinical trials
  • Mass screening
  • Prostate cancer
  • Prostate-specific antigen
  • Public health policy
  • Simulation modeling

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'What do the screening trials really tell us and where do we go from here?'. Together they form a unique fingerprint.

  • Cite this